alexa Generalized Pustular Psoriasis Associated with Ulcerative Colitis | Open Access Journals
ISSN: 2155-9554
Journal of Clinical & Experimental Dermatology Research
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Generalized Pustular Psoriasis Associated with Ulcerative Colitis

Ayako Shimizu*, Noriaki Kamada and Hiroyuki Matsue
Department of Dermatology, Chiba University, Graduate School of Medicine, Chiba, Japan
Corresponding Author : Ayako Shimizu
Department of Dermatology, Chiba University
Graduate School of Medicine 1-8-1 Inohana
Chuo-ku, Chiba, Japan 260- 8670
Phone: +81-43-226-2505
Fax: +81-43-226-2128
Email: ayakosmz@bu.edu
Received October 21, 2013; Accepted November 09, 2013; Published November 16, 2013
Citation: Shimizu A, Kamada N, Matsue H (2013) Generalized Pustular Psoriasis Associated with Ulcerative Colitis. J Clin Exp Dermatol Res 4:192. doi: 10.4172/2155-9554.1000192
Copyright: © 2013 Shimizu A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Visit for more related articles at Journal of Clinical & Experimental Dermatology Research

Abstract

A 38-year-old Japanese woman with steroid-dependent ulcerative colitis developed generalized pustular psoriasis. Cyclosporine improved both her cutaneous lesion and bowel condition. Recent studies show that Th17 T cells are critically involved in the pathogenesis of both generalized pustular psoriasis and inflammatory bowel disease. Although molecular mechanisms seem similar, our case is the first report showing generalized pustular psoriasis associated with inflammatory bowel disease. We believe that our case may contribute to further understanding of both diseases and give us a chance to design a suitable therapy in the case of generalized Pustular psoriasis complicating inflammatory bowel disease.

Keywords
Cyclosporine A; Inflammatory Bowel disease; Pustular psoriasis; Ulcerative colitis
Case Presentation
A 38-year-old Japanese woman presented with pustules and erythematous papules on her extremities. She had been treated with corticosteroids and salazosulfapyridine for Ulcerative Colitis (UC) for 5 years. Her doctor administered azathioprine to reduce her corticosteroid dose, and one month later, she developed the rash. Azathioprine was discontinued, and she was referred to our dermatology department. Topical corticosteroids resolved the cutaneous lesions in a week, but they relapsed one month later and worsened along with a bad bowel condition and a high fever. Sheets of erythema and pustulation spread over her extremities and trunk (Figure 1). Bacterial and fungal cultures were negative. Her blood contained elevated levels of neutrophils (7139/mm3) and C-reactive protein (2.6 mg/dl). Biopsy of an abdominal pustule showed a spongiform pustule of Kogoj formed by large collections of neutrophils in the upper spinous and granular layers (Figure 2). Epidermal changes consisted of parakeratosis and elongation of the rete ridges. The upper dermis contained an infiltrate of lymphocytes and neutrophils, migrating from the capillaries in the papillae into the epidermis. Generalized Pustular Psoriasis (GPP) was diagnosed, and etretinate 30 mg/day was started but was not effective. So Cyclosporine A (CSA) (150 mg/day=3.8 mg/kg/day) was added one week later. Within a week, the skin lesions and fever subsided. Neutrophils and C-reactive protein levels decreased to within normal ranges. Etretinate was tapered and discontinued after two months. Throughout these treatments, both her skin lesions and her bowel condition improved. Prednisolone was tapered and discontinued. We have continued this CSA dose for 2 years, because her bowel condition may deteriorate if we reduce it. Pustular eruptions have not relapsed to date, and the UC symptoms are well controlled.
Discussion
GPP is a rare but severe cutaneous disease, characterized by a sudden generalized eruption of sterile pustules on a highly erythematous skin surface accompanied by a high fever [1]. Cutaneous manifestations are well-recognized complications of Inflammatory Bowel Disease (IBD) [2]. The most common reactive skin eruptions are erythema nodosum, pyogenic gangrenosum and Sweet’s syndrome [2]. An association between IBD and psoriasis has also been observed; the prevalence of psoriasis is 7-11% in IBD, compared with a general population-based prevalence of 1-2% in North America and Europe [2]. However, no reports have shown GPP accompanying IBD, except for infliximab-induced GPP in patients with IBD [3-5]. GPP is divided into two groups, one with and one without a history of ordinary psoriasis [1]. Our patient had neither a history of cutaneous disease nor a family history of psoriasis. Differential diagnosis included pustular drug eruption, acute generalized exanthematous pustulosis, acute generalized pustular bacterid (Tan), pustular vasculitis and subcorneal pustular dermatosis (Sneddon-Wilkinson). Because the generalized pustular eruption appeared over one month after azathioprine discontinuation, drug eruption by azathioprine was excluded. She had taken salazosulfapyridine for five years when she suffered from generalized pustulosis, and she continues it now without cutaneous lesions, so salazosulfapyridine was excluded as well. The other differential diagnoses were excluded based on the histopathologic features. Although a relapsing course is important in the diagnosis of GPP, our case is controlled with CSA. GPP was confirmed by the clinical and pathological correlations.
In our patient, the conditions of GPP and UC seemed parallel. Both psoriasis and IBD are organ-specific autoimmune diseases which are triggered by an activated cellular immune system [6,7]. The balance between T-helper 17 cells (Th17) and regulatory T cells (Treg) plays a key role. Psoriasis shares many immune-derived cytokines with IBD, including IL-17, IL-23 and TNFs. The therapeutic strategies overlap considerably. In our case, CSA controlled both GPP and UC effectively. CSA inhibits interleukin-2 production by activated T lymphocytes through a calcineurin-dependent pathway [8]. CSA is a standard treatment for GPP, as are etretinate and methotrexate, and has been used to induce remission in acute severe UC [6,8]. Thus, this case demonstrates that CSA may be a candidate treatment for this rare combination of diseases.
References








Figures at a glance

image   image
Figure 1   Figure 2
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 11536
  • [From(publication date):
    November-2013 - Mar 26, 2017]
  • Breakdown by view type
  • HTML page views : 7782
  • PDF downloads :3754
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsonline.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsonline.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsonline.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsonline.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsonline.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsonline.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsonline.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsonline.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsonline.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsonline.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version